Ventolin Hfa is owned by Glaxosmithkline.
Ventolin Hfa contains Albuterol Sulfate.
Ventolin Hfa has a total of 4 drug patents out of which 0 drug patents have expired.
Ventolin Hfa was authorised for market use on 19 April, 2001.
Ventolin Hfa is available in aerosol, metered;inhalation dosage forms.
The generics of Ventolin Hfa are possible to be released after 26 August, 2026.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7832351 | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Jun, 2023
(2 months from now) | |
US7832351
(Pediatric) | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Dec, 2023
(8 months from now) | |
US7500444 | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Feb, 2026
(2 years from now) | |
US7500444
(Pediatric) | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Aug, 2026
(3 years from now) |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 19 April, 2001
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
3
European Union
2
Hong Kong
2
United States
2
Japan
2
Portugal
2
Denmark
2
Cyprus
2
Spain
2
United Kingdom
2
China
1
Germany
1
Brazil
1
South Africa
1
Austria
1
Canada
1
Mexico
1
Australia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic